Grazia Arpino

Summary

Affiliation: Federico II University
Country: Italy

Publications

  1. doi request reprint Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer
    Grazia Arpino
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy
    Oncology 77:23-37. 2009
  2. pmc Tumor characteristics and prognosis in familial breast cancer
    G Arpino
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
    BMC Cancer 16:924. 2016
  3. doi request reprint Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts
    G Arpino
    Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy Electronic address
    Crit Rev Oncol Hematol 99:81-90. 2016
  4. doi request reprint Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study
    Grazia Arpino
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S Pansini 5, 80131, Naples, Italy
    J Cancer Res Clin Oncol 142:669-78. 2016
  5. doi request reprint Features of aggressive breast cancer
    Grazia Arpino
    Universita di Napoli Federico II, Napoli, Italy Electronic address
    Breast 24:594-600. 2015
  6. pmc Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
    Grazia Arpino
    Department of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II Medical School, Via S Pansini 5, 80131, Naples, Italy
    Breast Cancer Res Treat 154:127-32. 2015
  7. doi request reprint Gene expression profiling in breast cancer: a clinical perspective
    Grazia Arpino
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy
    Breast 22:109-20. 2013
  8. doi request reprint Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives
    Francesco Schettini
    Medical Oncology, Department of Clinical and Surgical Medicine, University of Naples Federico II, Pansini 5, 80131 Naples, Italy Electronic address
    Cancer Treat Rev 50:129-141. 2016
  9. pmc Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
    Piera Gargiulo
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy
    BMC Cancer 16:375. 2016
  10. doi request reprint Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study
    Tiziana Pagano
    1Reproductive Medicine Unit, Department of Neuroscience, Reproductive Medicine, Odontostomatology2Medical Oncology, Department of Clinical and Surgical Medicine, University of Naples Federico II, Naples, Italy
    Menopause 23:1108-13. 2016

Detail Information

Publications12

  1. doi request reprint Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer
    Grazia Arpino
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy
    Oncology 77:23-37. 2009
    ....
  2. pmc Tumor characteristics and prognosis in familial breast cancer
    G Arpino
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
    BMC Cancer 16:924. 2016
    ....
  3. doi request reprint Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts
    G Arpino
    Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy Electronic address
    Crit Rev Oncol Hematol 99:81-90. 2016
    ..All dosing schedules were considered acceptable for fit patients with indolent disease. These recommendations are based on current evidence, and emerging data from ongoing trials may reinforce or modify the recommendations provided...
  4. doi request reprint Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study
    Grazia Arpino
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S Pansini 5, 80131, Naples, Italy
    J Cancer Res Clin Oncol 142:669-78. 2016
    ..However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC...
  5. doi request reprint Features of aggressive breast cancer
    Grazia Arpino
    Universita di Napoli Federico II, Napoli, Italy Electronic address
    Breast 24:594-600. 2015
    ..Breast cancer is a heterogeneous disease, both clinically and biologically, which may be responsible for the wide range of survival durations for patients with metastatic disease...
  6. pmc Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
    Grazia Arpino
    Department of Clinical Medicine and Surgery, Oncology Division, University of Naples Federico II Medical School, Via S Pansini 5, 80131, Naples, Italy
    Breast Cancer Res Treat 154:127-32. 2015
    ..These changes occurred during the first 2 years after diagnosis and were not specifically related to chemotherapy, menopausal status, or initial body weight. ..
  7. doi request reprint Gene expression profiling in breast cancer: a clinical perspective
    Grazia Arpino
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita di Napoli Federico II, Napoli, Italy
    Breast 22:109-20. 2013
    ....
  8. doi request reprint Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives
    Francesco Schettini
    Medical Oncology, Department of Clinical and Surgical Medicine, University of Naples Federico II, Pansini 5, 80131 Naples, Italy Electronic address
    Cancer Treat Rev 50:129-141. 2016
    ....
  9. pmc Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
    Piera Gargiulo
    Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy
    BMC Cancer 16:375. 2016
    ..Male breast cancer (MBC) is rare. Given the paucity of randomized trials, treatment is generally extrapolated from female breast cancer guidelines...
  10. doi request reprint Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study
    Tiziana Pagano
    1Reproductive Medicine Unit, Department of Neuroscience, Reproductive Medicine, Odontostomatology2Medical Oncology, Department of Clinical and Surgical Medicine, University of Naples Federico II, Naples, Italy
    Menopause 23:1108-13. 2016
    ..The aim of this study was to evaluate the effects of fractional microablative CO2 laser on sexual function and in relieving symptoms in women with breast cancer and VVA induced or exacerbated by iatrogenic menopause...
  11. pmc Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
    Grazia Arpino
    Department of Clinical Medicine, Division of Medical Oncology, University of Naples Federico II, Naples, Italy
    Anticancer Drugs 26:117-22. 2015
    ....
  12. ncbi request reprint A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Napoli, Italy
    Clin Cancer Res 11:4741-8. 2005
    ..Clinical data, however, have been conflicting. We have conducted a meta-analysis on the interaction between the response to endocrine treatment and the overexpression of HER-2 in metastatic breast cancer...